title: [Re-allign (randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran ftexilate in patients after heart valve replacement)].
authors: Universitätsklinikum Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland, zeus@med.uni-duesseldorf.de.
authors: T
authors: T
authors: Zeus
authors: S
authors: S
authors: Nitschmann
authors: M
authors: M
authors: Kelm
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000991:Antithrombins / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics*; D000069604:Dabigatran; D005260:Female; D019918:Heart Valve Prosthesis Implantation / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D013927:Thrombosis / Q000209:etiology / Q000378:metabolism* / Q000517:prevention & control*; D014018:Tissue Distribution; D016896:Treatment Outcome; D055815:Young Adult; D015091:beta-Alanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics
chemical_list: D000991:Antithrombins; D001562:Benzimidazoles; D015091:beta-Alanine; D000069604:Dabigatran